Trial Profile

Efficacy and long term safety of fenfluramine in patients with Dravet syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fenfluramine (Primary) ; Valproate
Indications Dravet syndrome
Focus Therapeutic Use

Most Recent Events

30 Aug 2018 Results presented in a Zogenix media release.
30 Aug 2018 According to a Zogenix media release, results (n=15) from this study were presented at the 13th European Congress on Epileptology (ECE).
23 Nov 2016 According to a Zogenix media release, new data will be presented at 70th Annual American Epilepsy Society Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com